Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE1831 in Relapsed/Refractory Systemic Lupus Erythematosus
NCT07314567Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2026
- Primary completion
- Oct 2027
- Modality
- Antibody-Drug Conjugates (ADCs), Native Immune Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of ACE1831 in systemic lupus erythematosus (SLE), sponsored by Tongji Hospital. Primary endpoint: Safety and Tolerability at 24 weeks. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ACE1831
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07314567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07314567.